Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
GetDeal Team
Contributor
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Related Articles
Lightspeed targets $250M for new India fund, focusing on early-stage AI
The venture firm is aligning its India fundraising cycle with its global funds for the first time, as it shifts to a shorter investment period.
Gemini 3.8 Live with Live Avatar gives Google’s AI a face
Google's new Gemini 3.8 Live update lets users have conversations with the model while watching an animated AI persona respond in real time. The "Live Avatar" will lip-sync and show different facial expressions during conversations, but it's currently only available to Gemini Enterprise customers. As noted by Google, Live Avatar can transition between the 97 languages it supports "without degrading video fidelity or introducing visual drift." One video shared by Google shows its Live Avatar talking in English and Japanese, with its mouth animation lining up with what it's saying in both languages. It can also pull up information on-screen w … Read the full story at The Verge.
PrismML brings its tiny LLMs to Qualcomm-powered smart glasses
Prism's larger goal is open-weight AI that runs on devices and makes better use of the computing power they already have.